<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935700</url>
  </required_header>
  <id_info>
    <org_study_id>2013-04-03(I)</org_study_id>
    <nct_id>NCT01935700</nct_id>
  </id_info>
  <brief_title>Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma</brief_title>
  <official_title>Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to evaluate the potential of colchicine for the palliative management of&#xD;
      hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the&#xD;
      Department of Health R.O.C. approved doses and methods of administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dosing schedule: 2 tablets (1 mg) three times per day (after breakfast, lunch and dinner);&#xD;
      continue 4 days and stop for 3 days (1 cycle)&#xD;
&#xD;
      Adjustment the dosage of colchicine during study:&#xD;
&#xD;
        1. The colchicine dosage will be changed when the hepatic reserved function of the&#xD;
           participant changes from Child A to B according to the following rules.&#xD;
&#xD;
             1. 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner;&#xD;
                continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients&#xD;
                quit this trial&#xD;
&#xD;
             2. If the hepatic reserved function of the participant returns to Child A, The dosage&#xD;
                for Child A will be restored.&#xD;
&#xD;
             3. If the hepatic reserved function of the participant changes to Child C, colchicine&#xD;
                will be stopped and participant receives regular follow-up only.&#xD;
&#xD;
        2. If participant suffers from severe diarrhea, colchicine will be temporarily stopped.&#xD;
           When the symptom of diarrhea subsides, colchicine will be given again according to the&#xD;
           following rules.&#xD;
&#xD;
             1. For participant receives﹝2 tablets after breakfast, 2 tablet after lunch and 2&#xD;
                tablets after dinner﹞, the dosage of colchicine will be changes to﹝2 tablets after&#xD;
                breakfast, 1 tablet after lunch and 2 tablets after dinner﹞.&#xD;
&#xD;
                If diarrhea attacks again, the dosage of colchicine will be changes to﹝2 tablets&#xD;
                after breakfast and 2 tablets after dinner﹞.&#xD;
&#xD;
                If diarrhea attacks again, the dosage of colchicine will be changes to﹝2 tablets&#xD;
                after breakfast, 1 tablet after dinner﹞.&#xD;
&#xD;
                If diarrhea also attacks again, colchicine will be stopped and participant receives&#xD;
                regular follow-up only.&#xD;
&#xD;
             2. For participant receives﹝2 tablets after breakfast, 1 tablet after lunch and 2&#xD;
                tablets after dinner﹞, the dosage of colchicine will be changes to﹝2 tablets after&#xD;
                breakfast and 2 tablets after dinner﹞.&#xD;
&#xD;
           If diarrhea attacks again, the dosage of colchicine will be changes to﹝2 tablets after&#xD;
           breakfast, 1 tablet after dinner﹞.&#xD;
&#xD;
           If diarrhea also attacks again, colchicine will be stopped and participant receives&#xD;
           regular follow-up only.&#xD;
&#xD;
        3. If the participant has one of the following conditions, colchicine will be temporarily&#xD;
           stopped. When the condition of the participant improves, colchicine will be given again&#xD;
           after the judgment from the doctor of the research team. For participants unable to&#xD;
           receive colchicine again, they will receive regular follow-up only.&#xD;
&#xD;
             1. There are life-threatening hemorrhage including gastrointestinal hemorrhage and&#xD;
                hemorrhage from other vital organs such as lungs or brain.&#xD;
&#xD;
             2. . There are life-threatening bacterial, fungal or viral infection (not included&#xD;
                hepatitis B and C virus).&#xD;
&#xD;
             3. . Patient has serum creatinine level &gt; 1.5 mg/dL.&#xD;
&#xD;
             4. . Patient has white blood cell count &lt; 1500/µL, platelet count &lt; 30000/µL or&#xD;
                hemoglobin &lt; 9.0 gm/dL after medication.&#xD;
&#xD;
             5. The research team decides that the participant is not suitable to continue the&#xD;
                study caused by abnormality of any vital organ or severe side effects caused by the&#xD;
                study.&#xD;
&#xD;
        4. Colchicine will be temporarily stopped one day before transcatheter arterial&#xD;
           chemoembolization until participant has body temperature &lt; 38 ℃, same hepatic reserved&#xD;
           function as before, and serum creatinine level &lt; 1.5 mg/d after embolization.&#xD;
&#xD;
      Follow-up procedures and items for the participants to co-operate:&#xD;
&#xD;
      All participants will be followed according to the guide line of the National Health Council&#xD;
      and the clinical practice in the treatment of hepatocellular carcinoma. Contrasted-enhanced&#xD;
      computed tomography or magnetic resonance imaging will be performed within every 3 to 4&#xD;
      months. Serum alpha-fetoprotein will be determined at least one session within every 2 to 3&#xD;
      months in patients with elevated serum alpha-fetoprotein levels. The hepatic and renal&#xD;
      function will be determined at least one session every month. The participants are asked to&#xD;
      visit our outpatient clinic at least one session every month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2013</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>opeo labeled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 72 months</time_frame>
    <description>The overall survival of the participants calculated from the date of enrollment to the date of death will be compared with the control group with the same TNM and the Barcelona Clinic Liver Cancer (BCLC) staging collected from 2005/1/1 to the end of this study. The overall survival of the control group was calculated from the date of receiving sorafenib treatment to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade III Severe Adverse Events</measure>
    <time_frame>up to 72 months</time_frame>
    <description>The type and frequency of grade III severe adverse events based on the Common Terminology Criteria for Adverse Events (CTCAE) noted during the study period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Metastasis</condition>
  <condition>Invasion</condition>
  <arm_group>
    <arm_group_label>colchicine treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Adjustment the dosage of colchicine during study:&#xD;
The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day.</description>
    <arm_group_label>colchicine treated patients</arm_group_label>
    <other_name>Colicine, Tunfon and others, Drugbank Accession Number DB01394, PubChem CID 6167, CAS Registry Number: 64-86-8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. . Patient has at least one of the following criteria: (1) positive for hepatocellular&#xD;
             carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level &gt; 400&#xD;
             ng/mL and has evidence of hepatocellular carcinoma provided by contrast-enhanced&#xD;
             computed tomography or magnetic resonance imaging.&#xD;
&#xD;
          2. . Contrast-enhanced computed tomography or magnetic resonance imaging has evidence of&#xD;
             distant metastasis or large vessel invasion caused by hepatocellular carcinoma.&#xD;
&#xD;
          3. . Patient has Child A hepatic reserved function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and&#xD;
             hemorrhage from other vital organs such as lungs or brain.&#xD;
&#xD;
          2. . There are life-threatening bacterial, fungal or viral infection (not included&#xD;
             hepatitis B and C virus).&#xD;
&#xD;
          3. . Patient has serum creatinine level &gt; 1.5 mg/dL.&#xD;
&#xD;
          4. . Patient must receive long-term medication of statin or fibrates drugs and these&#xD;
             medications can not be changed.&#xD;
&#xD;
          5. . Patient has white blood cell count &lt; 1500/µL, platelet count &lt; 30000/µL or&#xD;
             hemoglobin &lt; 9.0 gm/dL after medication.&#xD;
&#xD;
          6. . Pregnant woman or plan to be a pregnant woman&#xD;
&#xD;
          7. . allergy to colchicine or has history of severe side effects caused by colchicine&#xD;
&#xD;
          8. . Patient has received systemic chemotherapy within 2 months before enrollment or&#xD;
             plans to receive systemic chemotherapy in the future.&#xD;
&#xD;
          9. . Patient is under or plans to receive Nexavar or other clinical trial testing drug.&#xD;
&#xD;
         10. . Patient has severe malfunction of vital organs and can not participate in this study&#xD;
             justified by the doctor in this research team.&#xD;
&#xD;
         11. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zu Y Lin, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002. Epub 2013 Jul 16.</citation>
    <PMID>23871804</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2013</study_first_submitted>
  <study_first_submitted_qc>August 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <results_first_submitted>February 1, 2020</results_first_submitted>
  <results_first_submitted_qc>August 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 8, 2020</last_update_submitted>
  <last_update_submitted_qc>August 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Zu-Yau Lin</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT01935700/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>from 2013-6-6 to 2019-5-31 in Kaohsiung Medical University Hospital total 15 participants were included for screening, one screening failure, 14 participants received colchicine management</recruitment_details>
      <pre_assignment_details>one screening failure dut to active gastrointestinal hemorrhage</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colchicine Treated Patients</title>
          <description>The dosing schedule started from 1 mg three times per day after meal for 4 days and stopped for the following 3 days (1 cycle). This cycle was repeated till the participant quitted this trial.&#xD;
Adjustment of colchicine dosage during study:&#xD;
The colchicine dosage was changed when the hepatic reserved function of the participant changed from Child A to B or C according to the following rules.&#xD;
Total daily dose reduced to 2.5 mg (1mg morning, 0.5 mg afternoon, 1 mg night) for participant with Child class B.&#xD;
If the participant changed to Child class C, colchicine will be stopped and participant received regular follow-up only.&#xD;
Colchicine was temporarily stopped in participant suffered from diarrhea and was started again with reducing daily total dose of 0.5 mg.&#xD;
Colchicine was temporarily stopped when the participant fitted any of the exclusion criteria during the study, and was given again after the fitted exclusion criterion was eliminated.</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib Treated Group</title>
          <description>This group was originated from review of hepatocellular carcinoma patients (from January 1, 2014 to May 31, 2019) with the same condition as this trial selected participants and treated by sorafenib for more than 2 months by the research team.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The participant received more than 8 courses of colchicine management.</population>
      <group_list>
        <group group_id="B1">
          <title>Colchicine Treated Patients</title>
          <description>This group included participants receiving total daily colchicine dose equal or larger than 1.5 mg for more than 8 cycles (28 days).</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib Treated Group</title>
          <description>This group was originated from review of hepatocellular carcinoma patients (from January 1, 2014 to May 31, 2019) with the same condition as this trial selected participants and treated by sorafenib for more than 2 months by the research team.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="B2" value="62" lower_limit="26" upper_limit="83"/>
                    <measurement group_id="B3" value="62" lower_limit="26" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>sex</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Only Taiwanese were included.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Only Taiwanese were included.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>open labeled phase II for AJCC TNM IIIB to IVB hepatocellular carcinoma patient</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The overall survival of the participants calculated from the date of enrollment to the date of death will be compared with the control group with the same TNM and the Barcelona Clinic Liver Cancer (BCLC) staging collected from 2005/1/1 to the end of this study. The overall survival of the control group was calculated from the date of receiving sorafenib treatment to the date of death.</description>
        <time_frame>up to 72 months</time_frame>
        <population>median survival</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Group</title>
            <description>Participant received more than 8 courses of colchicine management.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Treated Group</title>
            <description>The control group was originated from review of hepatocellular carcinoma patients (from January 1, 2014 to May 31, 2019) with the same condition as this trial selected participants and treated by sorafenib for more than 2 months by the research team.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The overall survival of the participants calculated from the date of enrollment to the date of death will be compared with the control group with the same TNM and the Barcelona Clinic Liver Cancer (BCLC) staging collected from 2005/1/1 to the end of this study. The overall survival of the control group was calculated from the date of receiving sorafenib treatment to the date of death.</description>
          <population>median survival</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="123" upper_limit="1000"/>
                    <measurement group_id="O2" value="290" lower_limit="74" upper_limit="1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was defined as no statistically significant difference (P value &gt; 0.05) in median survival between the colchicine group and the sorafenib treated group.</non_inferiority_desc>
            <p_value>0.4593</p_value>
            <method>Mann-Whitney U test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was defined as no statistically significant difference (P value &gt; 0.05) in survival between the colchicine group and the sorafenib treated group.</non_inferiority_desc>
            <p_value>0.3290</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade III Severe Adverse Events</title>
        <description>The type and frequency of grade III severe adverse events based on the Common Terminology Criteria for Adverse Events (CTCAE) noted during the study period.</description>
        <time_frame>up to 72 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Group</title>
            <description>This included the events occured after the participant signed the inform consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib Treated Group</title>
            <description>This group was originated from review of hepatocellular carcinoma patients (from January 1, 2014 to May 31, 2019) with the same condition as this trial selected participants and treated by sorafenib for more than 2 months by the research team.</description>
          </group>
        </group_list>
        <measure>
          <title>Grade III Severe Adverse Events</title>
          <description>The type and frequency of grade III severe adverse events based on the Common Terminology Criteria for Adverse Events (CTCAE) noted during the study period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary tract obstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritonitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholangitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmar-plantar erythrodysesthesia syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleural effusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of pneumonia between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.0552</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of biliary tract obstruction between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.0184</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of cholangitis between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.0931</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of peritonitis between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.0506</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of sepsis between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of diarrhea between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.5374</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of anorexia between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.14</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of abdominal pain between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.4584</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of skin rash between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of palmar-plantar erythrodysesthesia syndrome between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of hypertension between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of hemorrhage between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.5958</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of hypoglycemia between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>0.14</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of hyperglycemia between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of hypocalcemia between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison the incidence of grade III adverse event of pleural effusion between two groups</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The threshold for statistically significant difference in incidence was P = 0.05.</non_inferiority_desc>
            <p_value>1</p_value>
            <p_value_desc>The threshold for statistically significant difference in incidence was P = 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 72 months</time_frame>
      <desc>The adverse event for diarrhea was defined as watery or not-formed stool passage for more than 3 times per day.</desc>
      <group_list>
        <group group_id="E1">
          <title>Colchicine Group</title>
          <description>2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial&#xD;
Colchicine: Adjustment the dosage of colchicine during study:&#xD;
The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib Treated Group</title>
          <description>The control group was originated from review of hepatocellular carcinoma patients (from January 1, 2014 to May 31, 2019) with the same condition as this trial selected participants and treated by sorafenib for more than 2 months by the research team.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>biliary tract obstruction</sub_title>
                <description>caused by previous irradiation therapy</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>peritonotis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE V3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="40" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="83" subjects_affected="36" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="28" subjects_affected="15" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="58" subjects_affected="31" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="29" subjects_affected="13" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>grade I or II</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zu-Yau Lin</name_or_title>
      <organization>Kaohsiung Medical University Hospital</organization>
      <phone>88677317123</phone>
      <email>linzuyau@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

